Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"BioAxone BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAxone BioSciences Announces Notice of Allowance that Expands Scope of Key ROCK Inhibitors for Treatment of Cerebral Aneurysms","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical"},{"orgOrder":0,"company":"BioAxone BioSciences","sponsor":"Neurelis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neurelis Announces Acquisition Of Rights To Portfolio Of NCE Compounds","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"BioAxone BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAxone BioSciences Announces Patent Issued for Pharmaceutical Compositions of BA-210, a Rho Inhibitor for the Treatment of Spinal Cord Injury","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by BioAxone BioSciences

    Menu

    BioAxone BioSciences

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              BioAxone BioSciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BioAxone BioSciences Announces Patent Issued for Pharmaceutical Compositions of BA-210, a Rho Inhibitor for the Treatment of Spinal Cord Injury

              Details:

              BA-210 (cethrin) is a first-in-class, topically applied, biologic Rho inhibitor, developed BA-210 to inactivate Rho and has brought the compound forward to clinical testing. BA-210 has both orphan drug status and Fast Track designation from the FDA.

              Lead Product(s): Cethrin

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: BA-210

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 22, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              BioAxone BioSciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Neurelis Announces Acquisition Of Rights To Portfolio Of NCE Compounds

              Details:

              Neurelis intends to submit an Investigational New Drug (IND) application with the FDA on BioAxone's lead compound, BA-1049, in 2022. BioAxone's lead product, BA-1049, offers an opportunity to treat CCMs by stabilizing lesions and by preventing new lesions from emerging.

              Lead Product(s): BA-1049

              Therapeutic Area: Neurology Product Name: BA-1049

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Neurelis

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition June 21, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              BioAxone BioSciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              BioAxone BioSciences Announces Notice of Allowance that Expands Scope of Key ROCK Inhibitors for Treatment of Cerebral Aneurysms

              Details:

              The latest notice covers the critical patent application (US 16/214,973) for the proprietary method of treatment of cerebral aneurysms with BA-1049 and other ROCK2 oral drug candidates now in development.

              Lead Product(s): BA-1049

              Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: BA-1049

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 28, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY